Related Experiment Video
Updated: Jul 7, 2026
12:43
Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
Published on: August 16, 2016
Intravenous inotropic agents in heart failure
N R Banner1, H Lyster, A Prabhakar
1Royal Brompton and Harefield NHS Trust, Harefield Hospital, Middlesex UB9 6JH.
British Journal of Hospital Medicine (London, England : 2005)
|February 26, 2008
Summary
Inotropic agents are common in intensive care but have limited value for heart failure patients. Prolonged use of these drugs increases mortality, despite improving cardiac output.
Area of Science:
- Cardiology
- Pharmacology
- Intensive Care Medicine
Background:
- Inotropes are frequently administered in critical care settings.
- Their role in managing heart failure is debated due to potential risks.
Purpose of the Study:
- To evaluate the efficacy and safety of inotropic agents in heart failure treatment.
- To analyze the association between inotrope use and patient mortality.
Main Methods:
- Review of clinical data on inotropic drug administration in intensive care units.
- Analysis of patient outcomes, including cardiac output and mortality rates.
Main Results:
- Inotropic agents can enhance cardiac contractility and improve cardiac output.
- However, sustained administration is linked to increased mortality in heart failure patients.
Conclusions:
- The therapeutic benefit of inotropes in heart failure is constrained.
- Risk-benefit assessment is crucial for judicious inotrope use in intensive care.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...